Schatz S, Falk M, Jóri B et al. Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer. 2020. Cancers. 12(6), 1685.
https://doi.org/10.3390/cancers12061685
Gautschi O, Bubendorf L, Leyvraz S, Menon R, Diebold J. Challenges in the Diagnosis of NTRK Fusion-Positive Cancers.2020. J Thorac Oncol. 15(7)e108-e110.
https://doi.org/10.1016/j.jtho.2019.05.001Giannini R, Moretti S, Colella R, Panfili M et al. Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like. 2019. J Clin Endocrinol Metab. Aug 1;104(8):3557-3575.
https://academic.oup.com/jcem/article-abstract/104/8/3557/5381919- Jaekel N, Siebolts U, Menon R, Bertrand M et al. Impact of Somatic Mutations on Outcome in Patients > 60 Years Old with Newly Diagnosed AML Treated with Response-Adapted Sequential Azacitidine and Induction Chemotherapy within the DRKS00004519 Trial (RAS-AZIC) of the East German Study Group of Hematology and Oncology (OSHO). 2019. Blood. 134 (Supplement_1): 1420.
https://doi.org/10.1182/blood-2019-127865
- Gautschi O, Menon R, Bertrand M, Murer C, Diebold J. Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma. 2020. J Thorac Oncol. Jan;15(1):e13-e15.
https://doi.org/10.1016/j.jtho.2019.07.027
- Michels S, Massutí B, Schildhaus HU, Menon R et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. 2019. J Thorac Oncol. 14(7):1266-1276.
https://www.ncbi.nlm.nih.gov/pubmed/30978502
- Ackermann S, Cartolano M, Hero B, Menon R et al. A mechanistic classification of clinical phenotypes in neuroblastoma. 2018. Science. 362(6419):1165-1170.
http://science.sciencemag.org/content/362/6419/1165
- Plenker D et al. Structural alterations of MET trigger response to MET kinase inhibition in lung adenocarcinoma patients. 2017. Clin Cancer Res. Accepted manuscript available online
http://clincancerres.aacrjournals.org/content/early/2017/12/28/1078-0432.CCR-17-3001
- Müller JN et al. Concordance between comprehensive cancer genome profiling in plasma and tumor specimens. 2017. J Thorac Oncol. 15(10):1503-1511.
https://doi.org/10.1016/j.jtho.2017.07.014
- Michels SYF et al. ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor. 2017. npj Precision Oncology. 1:4.
https://www.nature.com/articles/s41698-017-0004-3
- Heuckmann JM et al. Comprehensive Hybrid Capture-Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative by FISH. 2017. J Thorac Oncol 12(3):e22-e24.
https://www.ncbi.nlm.nih.gov/pubmed/28215724
- Menon R et al. A novel EGFRC797 variant detected in a pleural biopsy from an Osimertinib-treated patient using a comprehensive hybrid-capture based next-generation sequencing assay. 2016. J Thorac Oncol. 11(9):e105-7.
http://www.jto.org/article/S1556-0864(16)30090-9/abstract
- Rooney C et al. Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon. 2016. PLoS One. 11:e0149628.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764357/
- Gautschi O et al. Successful AZD9291 Therapy Based on Circulating T790M. 2015. J Thorac Oncol. 10:e122-3.
http://www.jto.org/article/S1556-0864(15)35115-7/abstract
- Gautschi O et al. Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy. 2015. Once Res Treat. 38:560-9.
http://www.karger.com/Article/FullText/441367
- Peifer M et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. 2015. Nature. 526:700-4.
http://www.ncbi.nlm.nih.gov/pubmed
- Heuckmann JM and Thomas RK. A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine. 2015. Ann Oncol. 26:1830-7.
http://annonc.oxfordjournals.org/content/26/9/1830.long
- George J et al. Comprehensive genomic profiles of small cell lung cancer. 2015. Nature. 524:47-53.
http://www.ncbi.nlm.nih.gov/pubmed
- Schramm A et al. Mutual dynamics between primary and relapse neuroblastomas. 2015. Nat Genet. 47:872-7.
http://www.ncbi.nlm.nih.gov/pubmed
- Dietlein F et al. Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. 2015. Cell. 162:146-59.
http://www.ncbi.nlm.nih.gov/pubmed
- Scheffler M et al. Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient. 2015. J Thorac Oncol. 10:e40-3.
http://www.ncbi.nlm.nih.gov/pubmed
- Kloth M et al. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. 2015. Gut.
http://www.ncbi.nlm.nih.gov/pubmed
- Mazières J et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. 2015. J Clin Oncol. 33:992-9.
http://www.ncbi.nlm.nih.gov/pubmed
- Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. 2014. Nature. 511:543-50.
http://www.nature.com/nature/journal/v511/n7511/full/nature13385.html
- Fernandez-Cuesta L et al. CD74-NRG1 fusion in lung adenocarcinoma. 2014. Cancer Discov. 4:415-22.
http://cancerdiscovery.aacrjournals.org/content/4/4/415.long
- Thomas RK. Overcoming drug resistance in ALK-rearranged lung cancer. 2014. N Engl J. 370:1250-1.
http://www.ncbi.nlm.nih.gov/pubmed
- Fernandez-Cuesta L et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. 2014. Nat Commun. 5:3518.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132974/
- Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. 2013. Sci Transl Med. 5:209ra153.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006630/
- Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. 2012. Nature. 489:519-25.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466113/
- Heuckmann JM et al. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibitor in lung cancer. 2012. J Clin Oncol. 30:3417-20.
http://www.ncbi.nlm.nih.gov/pubmed
- Peifer M et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. 2012. Nat Genet. 44:1104-10.
http://www.ncbi.nlm.nih.gov/pubmed
- Chmielecki J et al. Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. 2012. Genes Chromosomes Cancer. 51:54-65.
http://onlinelibrary.wiley.com/doi/10.1002/gcc.20930/epdf
- Heuckmann JM et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. 2011. Clin Cancer Res. 17:7394-401.
http://clincancerres.aacrjournals.org/content/17/23/7394.long
- Weiss J et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. 2010. Sci Transl Med. 2:62-93.
http://www.ncbi.nlm.nih.gov/pubmed
- Chmielecki J et al. Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. 2010. Nucleic Acids Res. 38:6958-96.
http://nar.oxfordjournals.org/content/38/20/6985.long
- Thomas RK et al. High-throughput oncogene mutation profiling in human cancer. 2007. Nat Genet. 39:347-51.
http://www.ncbi.nlm.nih.gov/pubmed
- Thomas RK et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. 2006. Nat Med. 12:852-5.
http://www.ncbi.nlm.nih.gov/pubmed
- Mueller J et al. Comparison of genomic alterations derived from matched tumor tissue and liquid biopsy. WCLC 2016. Abstract P2.03b-081.
Abstract. Poster.
- Wiest G et al. Detection of an EGFR Kinase Domain Duplication in a Lung Adenocarcinoma Patient by Liquid Biopsy using Hybrid Capture-based Next Generation Sequencing. DGHO 2016. Abstract 291.
Abstract. Poster.
- Mueller J et al. Hybrid-capture based sequencing assays to detect novel alterations in BRAF from tissue and liquid biopsies. ESMO 2016. Abstract 2761.
Abstract. Poster.
- Heukamp L et al. Detection of actionable genome alterations using hybrid capture based next generation sequencing technology- NEOplus and NEOliquid. ASCO 2016. Abstract e23181.
Abstract.
- Menon R et al. Identification of Therapeutically Targetable Genomic Alterations in a cohort of patients with CUP using a Hybrid-Capture based Next Generation Sequencing Assay. AACR 2016. Abstract 152.
Abstract. Poster.
- Menon R et al. NEOliquid: Detection of KIF5B-RET fusions in liquid biopsy samples. ELCC 2016. Abstract 431.
Abstract. Poster.
- Menon R et al. Discovery of a Novel EGFR Resistance Mutation by Capture Based NGS Following AZD9291 Treatment. Oncol Res Treat 2016;39(suppl 1):120.
Abstract. Poster.
- Dziadziuszko R et al. Discrepancies Between ALK FISH and Capture Based NEOplus Diagnostics. WCLC 2015. Abstract 2748.
Abstract. Poster.
- Menon R et al. Successful AZD9291 Therapy Based on NEOliquid Detection of Circulating T790M in a Liquid Biopsy Sample. 2015. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Abstract B135.
Abstract. Poster.